Named on 10 rounds in the feed, most often at Series C and in Biotech.
Rounds from 2022-04-06 to 2026-09-23
ROUNDS
10
joined, none as lead
ROUNDS JOINED · USD
$2.0B
across 10 rounds
CO-INVESTORS
82
most often with T. Rowe Price
Named on 10 rounds in the feed, most often at Series C and in Biotech.
Rounds from 2022-04-06 to 2026-09-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series E Verified against 4 of 37 sources | $311M | 2026-09-23 | [ PART ] |
Soley Therapeutics Soley Therapeutics is a biotech company that discovers and develops novel medicines by leveraging the sensing capabilities of human cells. | Series C Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2026-01-07 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-03 | [ PART ] |
Solve Therapeutics Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology. | Funding round Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-11-17 | [ PART ] |
Veradermics Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-10-16 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122.3M | 2025-10-16 | [ PART ] |
Kailera Therapeutics Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-09-27 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2022-04-06 | [ PART ] |